Header Logo

Connection

MICHAEL R MIGDEN to Skin Neoplasms

Back to Details
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Skin Neoplasms.
MICHAEL R MIGDEN
Connection Strength
6.320
Skin Neoplasms
  1. Current and emerging intralesional immunotherapies in cutaneous oncology. J Am Acad Dermatol. 2024 Nov; 91(5):910-921.
    View in: PubMed
    Score: 0.292
  2. Treatments on the horizon for locally advanced basal cell carcinoma. Cancer Lett. 2024 May 01; 589:216821.
    View in: PubMed
    Score: 0.287
  3. Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Eur J Dermatol. 2023 Jun 01; 33(3):280-286.
    View in: PubMed
    Score: 0.272
  4. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. Dermatol Clin. 2023 Jan; 41(1):23-37.
    View in: PubMed
    Score: 0.261
  5. Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma. Dermatol Surg. 2021 11 01; 47(11):1511-1512.
    View in: PubMed
    Score: 0.243
  6. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australas J Dermatol. 2022 Feb; 63(1):36-42.
    View in: PubMed
    Score: 0.243
  7. Do Not Mess With Tattoos? Mohs Micrographic Surgery for Basal Cell Carcinoma Within the State of Texas. Dermatol Surg. 2021 09 01; 47(9):1273-1275.
    View in: PubMed
    Score: 0.241
  8. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.239
  9. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. J Drugs Dermatol. 2021 02 01; 20(2):156-165.
    View in: PubMed
    Score: 0.231
  10. Multiple inguinal basal cell carcinomas in the setting of intertrigo. Indian J Dermatol Venereol Leprol. 2020 Jul-Aug; 86(4):469.
    View in: PubMed
    Score: 0.222
  11. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb; 16(4):11-19.
    View in: PubMed
    Score: 0.215
  12. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305.
    View in: PubMed
    Score: 0.215
  13. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020 06; 182(6):1369-1378.
    View in: PubMed
    Score: 0.213
  14. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):947-951.
    View in: PubMed
    Score: 0.210
  15. Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol. 2019 Sep; 15(27):3171-3184.
    View in: PubMed
    Score: 0.208
  16. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 01; 45(1):1-16.
    View in: PubMed
    Score: 0.200
  17. Mohs Micrographic Surgery for the Treatment of Cutaneous Metastases in a Patient With Papillary Thyroid Carcinoma. Dermatol Surg. 2018 11; 44(11):1457-1459.
    View in: PubMed
    Score: 0.198
  18. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351.
    View in: PubMed
    Score: 0.192
  19. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018 Mar; 64:1-10.
    View in: PubMed
    Score: 0.186
  20. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar; 14(6):515-525.
    View in: PubMed
    Score: 0.185
  21. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol. 2017 Jul; 77(1):55-62.e3.
    View in: PubMed
    Score: 0.177
  22. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep; 12(18):2095-105.
    View in: PubMed
    Score: 0.167
  23. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28.
    View in: PubMed
    Score: 0.155
  24. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2024 03 11; 12(3).
    View in: PubMed
    Score: 0.072
  25. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024 Feb; 35(2):221-228.
    View in: PubMed
    Score: 0.070
  26. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J Am Acad Dermatol. 2024 Feb; 90(2):414-418.
    View in: PubMed
    Score: 0.070
  27. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
    View in: PubMed
    Score: 0.060
  28. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
    View in: PubMed
    Score: 0.059
  29. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Adv Ther. 2021 05; 38(5):2365-2378.
    View in: PubMed
    Score: 0.058
  30. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42?months. J Am Acad Dermatol. 2021 Apr; 84(4):1162-1164.
    View in: PubMed
    Score: 0.057
  31. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.057
  32. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
    View in: PubMed
    Score: 0.057
  33. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.055
  34. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.054
  35. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol. 2019 Feb; 46(2):152-158.
    View in: PubMed
    Score: 0.050
  36. Mohs Mapping Fidelity: Optimizing Orientation, Accuracy, and Tissue Identification in Mohs Surgery. Dermatol Surg. 2018 Jan; 44(1):1-9.
    View in: PubMed
    Score: 0.047
  37. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
    View in: PubMed
    Score: 0.046
  38. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 05 16; 17(1):332.
    View in: PubMed
    Score: 0.045
  39. Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome. Lancet Oncol. 2016 12; 17(12):1631-1632.
    View in: PubMed
    Score: 0.043
  40. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601.
    View in: PubMed
    Score: 0.043
  41. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
    View in: PubMed
    Score: 0.041
  42. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
    View in: PubMed
    Score: 0.039
  43. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2.
    View in: PubMed
    Score: 0.039
  44. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 09; 27(3):327-41.
    View in: PubMed
    Score: 0.038
  45. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt. 2014; 19(11):117003.
    View in: PubMed
    Score: 0.035
  46. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol. 2013 Jul; 52(7):856-61.
    View in: PubMed
    Score: 0.034
  47. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9.
    View in: PubMed
    Score: 0.032
  48. Pilot clinical study for quantitative spectral diagnosis of non-melanoma skin cancer. Lasers Surg Med. 2010 Dec; 42(10):716-27.
    View in: PubMed
    Score: 0.029
  49. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol. 2023 06; 7:e2200490.
    View in: PubMed
    Score: 0.017
  50. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124.
    View in: PubMed
    Score: 0.011
  51. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.